lifastuzumab vedotin

Ligand id: 8405

Name: lifastuzumab vedotin

References
1. Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I et al.. (2018)
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Ann. Oncol., 29 (4): 917-923. [PMID:29401246]
2. Dennis M, Rubinfeld B, Polakis P. (2013)
Compositions and methods for the diagnosis and treatment of tumor.
Patent number: US8535675 B2. Assignee: Genentech, Inc.. Priority date: 30/11/2009. Publication date: 17/09/2013.